Navigating 8 Analyst Ratings For Alpine Immune Sciences
Portfolio Pulse from Benzinga Insights
Alpine Immune Sciences (NASDAQ:ALPN) has received 8 analyst ratings in the past three months, showing a bullish trend with an average 12-month price target of $46.12, marking a 38.37% increase from the previous target. Analysts from firms like Guggenheim and Morgan Stanley have adjusted their ratings and price targets, reflecting optimism about ALPN's future performance. The company's financial health is strong, with significant revenue growth, high net margin, and excellent ROE and ROA, indicating efficient management and operational capacity.
April 09, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Alpine Immune Sciences has received positive analyst ratings, with an updated average 12-month price target of $46.12, indicating a bullish outlook. The company's financial indicators such as revenue growth and ROE are strong, suggesting a positive short-term impact on its stock price.
The increase in the average price target to $46.12, along with significant revenue growth and superior financial metrics like ROE and ROA, suggests analysts are optimistic about ALPN's future. This positive sentiment from analysts, combined with strong financial performance, is likely to influence investor perception and drive short-term price appreciation.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100